PepGen Inc. (NASDAQ:PEPG) Q4 2022 Earnings Call Transcript

Laura Chico: Okay, thanks very much. And then maybe one quick follow-up just circling back with respect to the EDO platform and after the recent presentations at MDA, can you just remind us what are some of the differences in the physical properties for the cell penetrating peptide portion of EDO51 versus throughout this 5051? And I guess, stick to any other drivers or features that maybe driving the increased levels of exon-skipping observed versus the R6G analog, whether it’s just access to the nuclear compartment other things like that? That would be helpful. Thank you.

James McArthur: Yes, appreciate the question, Laura. So, our molecule is a shorter than 20 amino acid linear peptide, completely synthetic in nature comprising three motifs, two motifs do contain arginine, but those arginines are interspersed by non-natural amino acids, which confers much greater stability upon the peptide. They sandwiched between the two of them a short hydrophobic core that we believe is fundamentally essential in conjunction with these polyarginine sequences driving the peptide at oligo into the cell. So, we think that it’s a very different sequence with very different biology. And on the basis of both research and preclinical work, we believe not only we are getting better access to cells, but also better access of the oligonucleotide into the nucleus, of course, which is necessary to perform its role and function.

Laura Chico: Thanks very much.

Operator: Thank you. And this concludes the Q&A session. I’d now like to turn the call back over to James McArthur for any closing remarks.

James McArthur: Thank you, operator and thank you everybody for participating in today’s call. Have a great afternoon and evening depending on where you are. Thank you.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.